Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
$0.44
-2.2%
$0.61
$0.42
$2.40
$3.86M0.2222,941 shs4,804 shs
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
$0.58
+18.4%
$0.61
$0.45
$5.25
$12.73M-0.26227,508 shs1.23 million shs
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
$0.42
-10.6%
$0.79
$0.40
$477.00
$1.65M1.4876,089 shs63,942 shs
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
$0.70
-15.6%
$0.80
$0.50
$6.85
$3.81M1.44423,159 shs649,702 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
-2.10%-5.64%-26.33%-36.91%-76.90%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
+19.48%+5.40%-3.42%+2.33%-86.17%
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
-11.54%-20.00%-33.33%-88.49%-99.83%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-15.56%+7.12%-3.32%+6.93%-79.08%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
2.3868 of 5 stars
3.55.00.00.00.61.70.6
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
0.6286 of 5 stars
3.50.00.00.00.00.00.6
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
2.8095 of 5 stars
3.55.00.00.00.92.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/AN/AN/AN/A
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
3.00
Buy$7.001,107.94% Upside
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
3.00
Buy$500.00118,947.62% Upside
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
3.00
Buy$4.00470.78% Upside

Current Analyst Ratings

Latest EVOK, PBLA, PHIO, and KPRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/27/2024
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/27/2024
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
2/6/2024
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $4.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
$5.18M0.73N/AN/A($0.77) per share-0.58
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
N/AN/AN/AN/A$0.79 per shareN/A
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
N/AN/AN/AN/A($18.37) per shareN/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/AN/AN/AN/A$2.06 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
-$7.79M-$2.33N/AN/A-150.43%-517.99%-91.83%5/20/2024 (Estimated)
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
-$12.51MN/A0.00N/AN/A-131.68%-75.82%5/14/2024 (Estimated)
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
-$25.26M-$669.09N/AN/AN/AN/A-70,194.55%-172.92%5/2/2024 (Estimated)
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-$10.83M-$5.93N/AN/AN/A-134.66%-105.86%5/9/2024 (Estimated)

Latest EVOK, PBLA, PHIO, and KPRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/26/2024Q4 2023
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
-$24.34-$65.90-$41.56-$65.90N/AN/A
3/14/2024Q4 2023
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/A-$0.59-$0.59-$0.59N/A$1.68 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/AN/AN/AN/AN/A
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
N/AN/AN/AN/AN/A
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
N/AN/AN/AN/AN/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/A
2.25
2.09
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
N/A
2.90
2.90
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
N/A
0.25
0.25
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/A
5.70
5.71

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/A
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
76.97%
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
4.37%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
57.31%

Insider Ownership

CompanyInsider Ownership
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
11.78%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
1.50%
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
0.01%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
0.77%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
48.48 million7.48 millionNot Optionable
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
1226.26 million25.86 millionNot Optionable
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
63.48 million3.48 millionNot Optionable
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
94.59 million4.56 millionNot Optionable

EVOK, PBLA, PHIO, and KPRX Headlines

SourceHeadline
Why Is Penny Stock Phio Pharmaceuticals Trading Higher On Monday?Why Is Penny Stock Phio Pharmaceuticals Trading Higher On Monday?
benzinga.com - April 22 at 3:21 PM
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cellsIntratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
finance.yahoo.com - April 22 at 3:21 PM
Intratumoral Injection of Phios PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cellsIntratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
globenewswire.com - April 22 at 1:10 PM
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
globenewswire.com - April 16 at 7:30 AM
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
globenewswire.com - April 11 at 7:30 AM
National Spotlight Features Phio’s Innovative RNAi Technology PlatformNational Spotlight Features Phio’s Innovative RNAi Technology Platform
finance.yahoo.com - April 3 at 10:33 AM
National Spotlight Features Phios Innovative RNAi Technology PlatformNational Spotlight Features Phio's Innovative RNAi Technology Platform
globenewswire.com - April 3 at 7:30 AM
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business UpdatePhio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
globenewswire.com - April 2 at 7:30 AM
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological MalignanciesPhio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
finance.yahoo.com - March 21 at 7:52 AM
Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity ResearchPhio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research
globenewswire.com - March 13 at 2:00 PM
Phio Pharmaceuticals Corp PHIOPhio Pharmaceuticals Corp PHIO
morningstar.com - March 10 at 7:10 AM
Analysts Are Bullish on These Healthcare Stocks: Neurogene (NGNE), Akero Therapeutics (AKRO)Analysts Are Bullish on These Healthcare Stocks: Neurogene (NGNE), Akero Therapeutics (AKRO)
markets.businessinsider.com - March 6 at 6:26 PM
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin DisordersPhio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders
finance.yahoo.com - March 6 at 6:26 PM
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Companys Intellectual Property Position in Treating Aging Skin and Skin DisordersPhio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders
globenewswire.com - March 6 at 10:30 AM
Challenges and Opportunities for Key Players in the Hypopigmentation Disorder Product MarketChallenges and Opportunities for Key Players in the Hypopigmentation Disorder Product Market
opprairie.com - February 23 at 1:35 PM
Dry Age Related Macular Degeneration Market Report 2024: Global Trends, Forecasts and Competitive Analysis 2018-2023 and 2024-2030Dry Age Related Macular Degeneration Market Report 2024: Global Trends, Forecasts and Competitive Analysis 2018-2023 and 2024-2030
uk.finance.yahoo.com - February 14 at 10:33 AM
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and Phio Pharmaceuticals (PHIO)Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and Phio Pharmaceuticals (PHIO)
markets.businessinsider.com - February 6 at 1:30 PM
Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological MalignanciesPhio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
finance.yahoo.com - January 31 at 8:14 AM
Phio Pharmaceuticals: Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard; Transfer Of ListingPhio Pharmaceuticals: Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard; Transfer Of Listing
cbonds.com - January 28 at 12:19 PM
Recent Insider Activity Could Benefit Phio Pharmaceuticals Corp (PHIO)Recent Insider Activity Could Benefit Phio Pharmaceuticals Corp (PHIO)
knoxdaily.com - January 1 at 1:39 PM
Phio Pharmaceuticals files to sell 4.42M shares of common stock for holdersPhio Pharmaceuticals files to sell 4.42M shares of common stock for holders
msn.com - December 19 at 9:00 PM
Why Phio Pharmaceuticals Stock Is NosedivingWhy Phio Pharmaceuticals Stock Is Nosediving
msn.com - December 7 at 5:55 PM
Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross ProceedsPhio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds
finance.yahoo.com - December 7 at 12:54 PM
Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdatePhio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
finanznachrichten.de - November 10 at 1:31 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Evoke Pharma logo

Evoke Pharma

NASDAQ:EVOK
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Kiora Pharmaceuticals logo

Kiora Pharmaceuticals

NASDAQ:KPRX
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Panbela Therapeutics logo

Panbela Therapeutics

NASDAQ:PBLA
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of Panbela's investigative agent ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Phio Pharmaceuticals logo

Phio Pharmaceuticals

NASDAQ:PHIO
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.